B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo(Peter MacCallum Cancer Centre), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Jessica E. Hawley(Columbia University Irving Medical Center), Pasquale Rescigno(Institute of Cancer Research), Wei Yuan(Shanghai Public Health Clinical Center), Bora Gürel(Institute of Cancer Research), Daniel Westaby(Royal Marsden NHS Foundation Trust), Michael M. Shen(Columbia University Irving Medical Center), Antje Neeb(Institute of Cancer Research), Charles G. Drake(Columbia University Irving Medical Center), Bianca Calì(Institute of Oncology Research), Aleksandar Obradović(Columbia University), Mateus Crespo(Institute of Cancer Research), Denisa Bogdan(Institute of Cancer Research), Jan Rekowski(Institute of Cancer Research), Nina Tunariu(Leicester Royal Infirmary), Susana Miranda(Royal Marsden NHS Foundation Trust), Lewis Gallagher(Institute of Cancer Research), Ruth Riisnaes(Institute of Cancer Research), Chloe Baker(Institute of Cancer Research), Adam Sharp(Institute of Cancer Research), Alana H.T. Nguyen(Columbia University Irving Medical Center), Silvia Bressan(Università della Svizzera italiana), Ana Ferreira(Institute of Cancer Research), Lorenzo Buroni(Institute of Cancer Research), Andrea Alimonti(Veneto Institute of Molecular Medicine), Jon Welti(Institute of Cancer Research), Suzanne Carreira(Institute of Cancer Research), Maria D. Fenor de la Maza(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Cláudia Bertan(Institute of Cancer Research), Khobe Chandran(Royal Marsden NHS Foundation Trust), George Seed(Institute of Cancer Research)
Cited by 90
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k